内大麻素系统
多发性硬化
大麻素受体
大麻素
实验性自身免疫性脑脊髓炎
医学
大麻酚
中枢神经系统
神经科学
免疫学
受体
生物
大麻
兴奋剂
内科学
精神科
作者
Anna Maria Malfitano,Giuseppe Matarese,Maurizio Bifulco
出处
期刊:Cns & Neurological Disorders-drug Targets
[Bentham Science Publishers]
日期:2005-11-25
卷期号:4 (6): 667-675
被引量:20
标识
DOI:10.2174/156800705774933087
摘要
An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of multiple sclerosis, including spasticity and pain. Endogenous molecules with cannabinoid-like activity, such as the "endocannabinoids", have been shown to mimic the anti-inflammatory properties of cannabinoids through the cannabinoid receptors. Several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis. Indeed, they can down regulate the production of pathogenic T helper 1-associated cytokines enhancing the production of T helper 2-associated protective cytokines. A shift towards T helper 2 has been associated with therapeutic benefit in multiple sclerosis. In addition, cannabinoids exert a neuromodulatory effect on neurotransmitters and hormones involved in the neurodegenerative phase of the disease. In vivo studies using mice with experimental allergic encephalomyelitis, an animal model of multiple sclerosis, suggest that the increase of the circulating levels of endocannabinoids might have a therapeutic effect, and that agonists of endocannabinoids with low psychoactive effects could open new strategies for the treatment of multiple sclerosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI